pepR‑MS enables mapping of >34,000 protein‑RNA crosslinks at single‑amino‑acid resolution in breast cancer cells

The Question

Mapping where proteins touch RNA inside living cells has been hampered by standard cross‑linking workflows that strip away most of the RNA strand. Without the RNA sequence, researchers cannot pinpoint the exact nucleotide that contacts a given amino acid. This blind spot limits our ability to decode regulatory networks that drive cancer cell behavior.

The Experiment

Using a photocrosslinking mass‑spectrometry (MS) platform dubbed pepR‑MS, the team engineered a workflow that preserves RNA fragments of selectable length while enriching peptide‑RNA adducts. The protocol was applied to cultured breast cancer cells; the abstract does not disclose the exact number of biological replicates or cell count. Primary outcomes included the count of unique peptide‑RNA crosslinks, the number of proteins harboring such links, and the length of retained RNA chains.

What They Found

By trimming the attached RNA to minimal size, pepR‑MS uncovered over 34,000 unique crosslinks spanning 589 proteins. Adjusting nuclease digestion allowed retention of RNA pieces up to five nucleotides, which were sequenced alongside the peptide. The accompanying computational pipeline, SALT, assigned peptide‑RNA sequence pairs for more than 1,600 crosslinks in a single LC‑MS run.

Why It Matters

The ability to resolve protein‑RNA contacts at single‑amino‑acid and single‑nucleotide precision opens a new window onto post‑transcriptional regulation. In breast cancer cells, many identified interfaces reside in intrinsically disordered regions, suggesting that flexible domains may mediate RNA binding more broadly than previously appreciated. Such detailed maps could guide the design of molecules that disrupt pathogenic protein‑RNA interactions without affecting the broader transcriptome.

Study Limitations

• The abstract omits concrete sample‑size information, making it difficult to assess statistical robustness.


• All data derive from a single breast cancer cell line, limiting generalizability to other tissue types or in‑vivo contexts.


• The workflow demands specialized MS instrumentation and custom software, which may restrict reproducibility in laboratories lacking those resources.

Practical Application

It is too early to apply pepR‑MS findings to a personal performance‑optimization protocol. Translating these proteomic maps into actionable strategies would first require validation of key protein‑RNA contacts in primary human tissues, functional assays demonstrating that modulating those interfaces alters cellular phenotypes, and replication of the method across diverse cell types. Only after such steps could a practitioner consider targeting specific interactions for performance‑related outcomes.

Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before modifying your diet, supplementation, or exercise routines. The scientific studies cited reflect the state of knowledge at their publication date and may be subject to revision.